Clarivate Epidemiology has created a robust repository of the prevalence of biomarker- and mutation-defined treatment-eligible cancer populations. Using Clarivate’s Biomarker Epidemiology, you can now save months of time and resources researching individual tumors in which a biomarker may be significant by quickly accessing data on the size of biomarker patient populations, based on diverse eligibility criteria and treatment settings.
In addition to an extensive literature review and modeling, we leverage our in-house estimates of cancer incidence for solid and hematological malignancies. All estimates are rigorously researched and transparently reported.
RAS mutation Epidemiology enables you to accomplish the following: